Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Cost Reimbursement

Drugs

Locations

Clinical Specialty

801-820 of 991 trials

Complicated Urinary Tract Infections in Children: Vabomere Study

We are studying the safety and effectiveness of Vabomere for children aged 3 months to under 12 years with complicated urinary tract infections. This research aims to improve treatment options for these young patients.

Complicated Urinary Tract InfectionAcute Pyelonephritis>2 yearsEfficacy phase (II)6-10 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteInfectious DiseasesUrology

Alzheimer’s Disease: KarXT for Psychosis

We are testing a new treatment called KarXT for people with psychosis associated with Alzheimer’s disease. The study aims to see if it can reduce symptoms like hallucinations and delusions compared to a placebo.

Psychosis Associated with Alzheimer's Disease3-6 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPsychiatry

Genital Herpes: IM-250 Treatment Study

We are investigating a new medication, IM-250, for people with recurrent genital herpes to see if it can help reduce outbreaks. The study will also look at the safety of this treatment when given weekly.

Genital Herpes≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visits Investigational Medicines Cost ReimbursementDermatologyInfectious Diseases

Acute Bacterial Skin Infections: IV Oritavancin for Kids

We are studying a single-dose intravenous medication for children with acute bacterial skin infections. The trial aims to assess its safety and how well it works compared to existing treatments.

Acute Bacterial Skin and Skin Structure Infection>2 yearsEfficacy phase (II)6-10 visits No Placebo Standard Medicines Cost ReimbursementDermatologyPediatrics

Seizures in Developmental and Epileptic Encephalopathies: LP352 Study

We are investigating whether LP352 can help reduce seizures in children and adults with developmental and epileptic encephalopathies. This study compares the medication to a placebo to assess its effectiveness and safety.

Developmental and Epileptic EncephalopathiesConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Obstructive Colon Cancer: Neoadjuvant Chemotherapy Study

We are studying whether two chemotherapy regimens can improve treatment outcomes for patients with obstructive colon cancer after colostomy. The goal is to see if starting chemotherapy before surgery leads to better recovery and survival rates.

Colon Cancer>2 yearsConfirmation phase (III)11-15 visits No Placebo Standard Medicines Cost ReimbursementGastroenterologyOncology

Multifocal Motor Neuropathy: Empasiprubart vs. IVIg

We are studying whether Empasiprubart can improve muscle strength and function in adults with Multifocal Motor Neuropathy compared to standard IVIg treatment.

Multifocal Motor Neuropathy>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineNeurology

Friedreich Ataxia: Vatiquinone Safety Study

We are studying the long-term safety of vatiquinone in patients with Friedreich Ataxia who have previously used this medication. We aim to see how it affects their symptoms over time.

Friedreich's Ataxia>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementNeurology

Clebopride for the Treatment of Rumination Syndrome

We are studying whether clebopride can improve symptoms in people suspected of having rumination syndrome. The trial compares its effects to a placebo to see how well it works.

Rumination Syndrome≤3 monthsMonitoring phase (IV)≤5 visits Investigational Medicines Cost Reimbursement Partially RemoteGastroenterology

Diabetic Cardiovascular Autonomic Neuropathy: The FibroCAN Study

We are investigating whether finerenone can help improve heart function and reduce nerve damage in people with type 2 diabetes and early-stage cardiovascular autonomic neuropathy. This study compares the treatment to a placebo to assess its effects.

Diabetic Cardiovascular Autonomic Neuropathy1-2 yearsEfficacy phase (II)6-10 visits Investigational Medicines Cost ReimbursementCardiologyEndocrinologyNeurology

Primary Sjögren's Disease: Efgartigimod Treatment Study

We are testing a new medication, efgartigimod, for adults with Primary Sjögren's Disease to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Sjögren's Syndrome>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Acromegaly: Debio 4126 Treatment Study

We are testing a new formulation of Debio 4126 in patients with acromegaly who have been treated with other medications. The study aims to see if it helps maintain normal hormone levels and evaluates its safety compared to a placebo.

Acromegaly1-2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementEndocrinology

Immune-Related Rheumatological Events in Cancer Patients

We are collecting data on how to better diagnose and manage joint and muscle issues caused by cancer treatments. This study involves multiple centers to improve care for patients receiving checkpoint inhibitors.

Cancer (all types)>2 yearsEfficacy phase (II)≤5 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncologyRheumatology

Gastric Cancer: HLX22 Treatment Study

We are studying a new drug, HLX22, combined with standard treatments for patients with advanced gastric cancer. The goal is to see if it works better and is safe compared to existing treatment options.

Gastric Cancer>2 yearsConfirmation phase (III)Post-Trial Drug Access Standard Medicines Cost ReimbursementGastroenterologyOncology

Atherosclerotic Cardiovascular Disease: Maridebart Cafraglutide

We are studying whether maridebart cafraglutide can improve heart health in people with atherosclerotic cardiovascular disease who are overweight or obese. This trial compares its effects to a placebo alongside standard care.

Arteriosclerotic Cardiovascular DiseaseConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost ReimbursementCardiologyInternal Medicine

Maridebart Cafraglutide for Heart Failure and Obesity

We are studying whether maridebart cafraglutide can improve heart failure symptoms and reduce hospital visits for people with heart failure and obesity. This trial compares the new treatment to a placebo alongside standard care.

Heart FailureConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

MMRd Uterine Cancer: Pembrolizumab Treatment Study

We are investigating whether pembrolizumab can effectively treat MMRd uterine cancer before surgery. The study will assess how well it works and its safety for patients.

Endometrial Cancer1-2 yearsEfficacy phase (II)6-10 visits No Placebo Standard Medicines Cost ReimbursementGynecology and ObstetricsOncology

Multiple Sclerosis: IMU-838 Treatment Study

We are investigating the effects of a new medication, IMU-838, on disease activity in people with relapsing-remitting multiple sclerosis. This study aims to understand how well it works and how safe it is compared to a placebo.

Relapsing-Remitting Multiple Sclerosis3-6 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementNeurology

Cutaneous Lupus Erythematosus: IMVT-1402 Study

We are evaluating a new treatment for people with active cutaneous lupus erythematosus to see if it improves skin symptoms compared to a placebo. This study aims to assess its safety and effectiveness.

Skin Lupus1-2 yearsEfficacy phase (II)Investigational Medicines Cost ReimbursementDermatologyRheumatology

Pulmonary Arterial Hypertension: Inhaled GB002 Study

We are evaluating the long-term safety and effects of an inhaled medication for people with pulmonary arterial hypertension. The study aims to see if it helps improve exercise capacity and overall well-being.

Pulmonary Arterial Hypertension>2 yearsEfficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteCardiologyPulmonology

Search Clinical Trials in the European Union